ImmunityBio and Rafa Win Israeli Approval for ANKTIVA Plus BCG
Israel approved ANKTIVA plus BCG for bladder cancer, according to the headline.
Related stories
NHTSA Opens Probe Into 1.2 Million Ford Vehicles Over Airbag Burn Risk
The National Highway Traffic Safety Administration is investigating certain Ford vehicles following reports of burn injuries caused by airbag deployments. Its preliminary evaluatio
M impact | REGULATION | Nov 09, 2026, 12:57 PM UTC
FDA Rejects Novocure’s Optune Mya Application for Brain Metastases
Novocure said it received a “not approvable” letter from the FDA for its U.S. premarket application for Optune Mya, a treatment for brain metastases.
M impact | REGULATION | Nov 09, 2026, 12:46 PM UTC
ImmunityBio Reports Q3 Revenue of $48.7 Million, Up 53%
ImmunityBio reported net product revenue of $48.7 million for the third quarter of 2026, up 53% year over year. U.S. revenue for the first nine months rose 92% to $143.6 million. T
M impact | EQUITY | Nov 09, 2026, 12:30 PM UTC
NHTSA Opens Probe Into 1.2 Million Ford Vehicles Over Airbags
NHTSA opened a preliminary evaluation after accidental deployment of seat-mounted side airbags caused serious burn injuries. The agency said it received eight complaints and four e
M impact | REGULATION | Nov 09, 2026, 11:11 AM UTC
NHTSA Opens Recall Query Into 2,895 Waymo Vehicles
NHTSA opened a recall query over continued traffic safety violations involving stopping for a school bus.
M impact | REGULATION | Nov 09, 2026, 10:53 AM UTC
NHTSA Opens Preliminary Evaluation Into 1,236,155 Ford Vehicles
NHTSA opened a preliminary evaluation involving an estimated 1,236,155 Ford vehicles over seat-mounted side airbags reportedly resulting in serious burn injuries.
M impact | REGULATION | Nov 09, 2026, 10:51 AM UTC